Table 2.
Administered chemotherapies before nal-IRI treatment.
| Line of nal-IRI treatment | 2nd line n = 30 (%) |
3rd line n = 14 (%) |
4th line n = 6 (%) |
5th line n = 1 (%) |
|---|---|---|---|---|
| Previous therapy | ||||
| Gemcitabine | 30 (100) | 14 (100) | 6 (100) | 1 (100) |
| Nab-paclitaxel | 25 (83) | 10 (71) | 4 (67) | 1 (100) |
| Oxaliplatin | 0 (0) | 10 (71) | 5 (83) | 1 (100) |
| Irinotecan | 0 (0) | 3 (21) | 4 (67) | 1 (100) |
| Fluoropyrimidines | 0 (0) | 11 (79) | 5 (83) | 1 (100) |
| Chemoradiation | 0 (0)) | 1 (7) | 2 (33) | 0 (0) |
| Erlotinib | 0 (0) | 1 (7) | 1 (17) | 0 (0) |
nal-IRI, nanoliposomal irinotecan.